FOLH1 and neoplasm: Hence, future clinical work is expected to be focused on less pretreated patients and should include further trials with real-world data analyses to optimize the therapy administration schemes, tumor radiation dose delivery, and efficacy; this will allow for us to fully exploit the high potential of PSMA-617 radionuclide therapy.